Bosentan in pulmonary hypertension associated with hypoxaemic lung diseases

Current Medical Research and Opinion

Volumn 23, Issue SUPPL. 2, 2007, Pages

  Roig Figueroa, Vicente ^a   Herrero Perez A ^a   Abad Lecha, E ^a   Ramos Cancelo, I ^a   Vielba Ramos, D ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

Author keywords

Bosentan; Endothelin; Evaluation studies; Oxygen inhalation therapy; Pulmonary hypertension; Respiratory tract diseases

Indexed keywords

ACETYLCYSTEINE; AZATHIOPRINE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BOSENTAN; DIGOXIN; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; PHOSPHODIESTERASE V INHIBITOR; PREDNISONE; PROSTANOID; STEROID; THEOPHYLLINE; TIOTROPIUM BROMIDE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTERIAL OXYGEN TENSION; BRONCHIECTASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC RESPIRATORY FAILURE; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FIBROSING ALVEOLITIS; HUMAN; HYPOXEMIA; LUNG ARTERY PRESSURE; LUNG RESECTION; MALE; MEAN ARTERIAL PRESSURE; OXYGEN THERAPY; PULMONARY HYPERTENSION; SILICOSIS;

EID: 34547468844     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X199538     Document Type: Conference Paper

References (26)

1. Barbera JA, Peinado VI, Santos S. Pulmonary hypertension in chronic obstructive pulmonary disease. Eur Respir J 2003;21:892-905
2. Shorr AF, Davies DB, Nathan SD. Outcomes for patients with sarcoidosis awaiting lung transplantation. Chest 2002;122:233-8
3. Kessler R, Faller M, Weitzenblum E, et al. 'Natural history' of pulmonary hypertension in a series of 131 patients with chronic obstructive lung disease. Am J Respir Crit Care Med 2001;164:219-24
4. Kessler R, Faller M, Fourgaut G, et al. Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;159:158-64
5. Oswald-Mammosser M, Weitzenblum E, Quoix E, et al. Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure. Chest 1995;107:1193-8
6. King TE, Jr., Tooze JA, Schwarz MI, et al. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 2001;164:1171-81
7. Higenbottam T. Pulmonary Hypertension and chronic obstructive pulmonary disease. A case for treatment. Proc Am Thorac Soc 2005;2:12-9
8. Thabut G, Dauriat G, Stern JB, et al. Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest 2005;127:1531-6
9. Weitzenblum E, Sautegeau A, Ehrhart M, et al. Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1985;131:493-8
10. Saadjian AY, Philip-Joet FF, Vestri R, Arnaud AG. Long-term treatment of chronic obstructive lung disease by Nifedipine: an 18-month haemodynamic study. Eur Respir J 1988;1:716-20
11. Barbera JA, Riverola A, Roca J, et al. Pulmonary vascular abnormalities and ventilation-perfusion relationships in mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1994;149(2 Pt 1):423-9
12. Nikolaou E, Trakada G, Prodromakis E, et al. Evaluation of arterial endothelin-1 levels, before and during a sleep study, in patients with bronchial asthma and chronic obstructive pulmonary disease. Respiration 2003;70:606-10
13. Yamakami T, Taguchi O, Gabazza EC, et al. Arterial endothelin-1 level in pulmonary emphysema and interstitial lung disease. Relation with pulmonary hypertension during exercise. Eur Respir J 1997;10:2055-60
14. Giaid A, Yanagisawa M, Langleben D et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993;328:1732-9
15. Chen SJ, Chen YF, Meng QC et al. Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J Appl Physiol 1995;79:2122-31
16. Roux S, Breu V, Ertel SI, Clozel M. Endothelin antagonism with bosentan: a review of potential applications. J Mol Med 1999;77:364-76
17. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903
18. McLaughlin VV, Sitbon O, Badesch DB et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005;25:244-9
19. Sulica R, De Palo L, Fearon-Clarke J et al. Bosentan is effective and safe in pulmonary hypertension associated with disorders of the respiratory system or hypoxemia. Proc Am Thorac Soc 2005;2:A204
20. Davie N, Haleen SJ, Upton PD, et al. ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med 2002;165:398-405
21. Park SH, Saleh D, Giaid A, Michel RP. Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. Am J Respir Crit Care Med 1997;156(2 Pt 1):600-8
22. Keane MP, Belperio JA, Dy M, et al. Bosentan inhibits angiogenesis in pulmonary fibrosis. Am J Respir Crit Care Med 2004;169:A777
23. Heath D, Smith P, Rios DJ, et al. Small pulmonary arteries in some natives of La Paz, Bolivia. Thorax 1981;36:599-604
24. Dawes KE, Peacock AJ, Gray AJ, et al. Characterization of fibroblast mitogens and chemoattractants produced by endothelial cells exposed to hypoxia. Am J Respir Cell Mol Biol 1994;10:552-9
25. Kourembanas S, Marsden PA, McQuillan LP, Faller DV. Hypoxia induces endothelin gene expression and secretion in cultured human endothelium. J Clin Invest 1991;88:1054-7
26. Eddahibi S, Chaouat A, Morrell N, et al. Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive pulmonary disease. Circulation 2003;14;108:1839-44